论文部分内容阅读
卵巢癌病死率居妇科恶性肿瘤之首,因其发病隐匿,80%患者就诊时已属中晚期,因此,对其早期诊断是提高患者生存率的关键因素之一。靶向超声分子显像为早期定性、定位诊断卵巢癌提供了可能。纳米级微泡造影剂具有血管穿透力强和聚集显像特点。将特异性抗体或配体连接到微泡表面,构建出肿瘤靶向性微泡造影剂,当这种造影剂进入体内后,通过配体与受体结合,就能选择性聚集并较长时间驻留于靶组织和器官,从而产生分子水平显像,显著提高了超声对早期病变组织的检测能力。包裹治疗基因、药物的靶向造影剂被超声破坏后,在靶部位释放治疗基因、药物,实现主动和被动靶向,从而提高治疗效果。
Ovarian cancer mortality ranks first in gynecological malignancies, because of its occult onset, 80% of patients are already in advanced stages of treatment, therefore, its early diagnosis is to improve the survival rate of patients is one of the key factors. Targeted ultrasound molecular imaging for the early qualitative, localization of ovarian cancer may provide a diagnosis. Nanoscale microbubble contrast agent with vascular penetration and aggregation imaging features. Specific antibodies or ligands are attached to the surface of microbubbles to construct tumor-targeted microbubble contrast agents. When such contrast agents enter the body, they can selectively aggregate for a longer period of time by binding ligands to the receptors Resides in the target tissues and organs, resulting in molecular level imaging, significantly improving the ability of ultrasound to detect early lesions. Wrapped therapeutic gene, the targeted contrast agent of the drug is destroyed by ultrasound, release the therapeutic gene and drug in the target site, and realize active and passive targeting to improve the therapeutic effect.